Navigation Links
Scarguard Labs, LLC Appoints Richard E. Pino as CFO

GREAT NECK, N.Y., Jan. 14 /PRNewswire/ -- Scarguard Labs, LLC, a closely held company specializing in the treatment of scars and other dermatological problems through the use of multi-technology drugs enhanced by a proprietary contact delivery system, announced it has appointed Richard E. Pino as Chief Financial Officer. He will be responsible for the Company's finance, accounting, and treasury functions and will report to Chief Executive Officer, Joel Studin, MD.

Prior to his appointment, Mr. Pino served as Chief Financial Officer / Chief Operating Officer for EcoSys Management LLC, a leader in enterprise project and operations financial management solutions. While there, Mr. Pino was responsible for overall operations: Finance, HR, Legal and Facilities. Previously, Mr. Pino was the Chief Financial Officer for The Relegence Corporation, which became a wholly-owned subsidiary of AOL, a TimeWarner Company during Pino's tenure.

From 2001 through 2005, Pino was the CFO for Frontline Communications International, Inc. where he was responsible for overall operations as well as overseeing outside accounting, tax and legal firms. Prior to 2001, Mr. Pino held various financial positions in of the following industries: Telecom, investment banking and media. He currently serves in a financial capacity on the boards of several non-profit organizations, including The Brooklyn Philharmonic and the Museum of Biblical Art.

Mr. Pino received his BA from St. Francis College in 1990 and his MBA from Adelphi University in 1993.

Speaking of Mr. Pino's appointment, Dr. Studin said, "We couldn't be happier that Richard agreed to join our Company. His experience covers all aspects of the finance, treasury and accounting roles, and includes strategic planning, mergers and acquisitions, all roles that he will fulfill while at Scarguard. He will be a key part of Scarguard's growth as a company."

About Scarguard Labs, LLC.

Scarguard Labs, LLC is a closely held pharmaceutical company specializing in dermatological medications employing an internationally patented delivery system designed to enhance drug effectiveness utilizing a multi-technology approach. Our flagship product, Scarguard, is the most frequently dispensed product for scars in plastic surgery offices since 2001. In addition, it can be found in most pharmacies, drug distributors and major grocery chains throughout the United States. We have multiple topical prescription and non-prescription drugs in the marketplace, or in varying stages of development. For more information, please visit our website at

    Company Contact:
    Richard E. Pino
    Chief Financial Officer /Investor Relations
    Scarguard Labs, LLC

    Investor Relations:
    John McNamara
    Cameron Associates
    (212) 245-8800 Ext. 205

SOURCE Scarguard Labs, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Scarguard Labs, LLC Expands Distribution Reach Through Agreements With McKesson Drugs and Publix Supermarkets
2. Innovatech Labs, Assisting Companies in Adhering to Halogen-Free Manufacturing Standards Aimed at Protecting the Environment
3. ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding
4. Access MediQuip Appoints Former Priority Healthcare CEO to Chairman of the Board
5. Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
6. ev3 Inc. Appoints Shawn McCormick as New Sr. Vice President and Chief Financial Officer
7. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
8. Hillenbrand, Inc. Appoints Jan Santerre Vice President of Lean Business
9. Appoints Kevin N. McGrath as President and CEO
10. Bon Secours Charity Health System Appoints Terence M. O'Brien as Chief Executive Officer
11. Bat Saliva-Based Stroke Drug Disappoints in Trial
Post Your Comments:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: